Tumor immune microenvironment (TIME) consists of intra-tumor immunological components
and plays a significant role in tumor initiation, progression, metastasis, and response to …

Chimeric antigen receptor (CAR)-T cell therapy represents a landmark advance in
personalized cancer treatment. CAR-T strategy generally engineers T cells from a specific …

Simple Summary Immunotherapies have changed the way we treat cancer and, while some
patients have benefitted greatly, there are still those that do not respond to therapy …

Immunotherapy plays a key role in cancer treatment, however, responses are limited to a
small number of patients. The biological basis for the success of immunotherapy is the …

T-cells genetically engineered to express a chimeric antigen receptor (CAR) have shown
remarkable results in patients with B-cell malignancies, including B-cell acute lymphoblastic …

The tumor microenvironment (TME) constitutes a dynamic system comprising tumor cells,
stromal cells and inflammatory cells, among others. Within this milieu, tumor cells adapt …

Immunotherapies have revolutionized cancer treatment approaches. Because not all
patients respond positively to immune therapeutic agents, it represents a challenge for …

The advances in immunotherapies in the last decades have brought new hope in the battle
against cancer (Wang et al., 2019; Morad et al., 2021). These therapies include immune …

Simple Summary Cell-to-cell communication between the immune system and tumors is of
the utmost importance; it influences the development of tumors, their growth, and how they …

Despite significant progress in cancer diagnostics and development of novel therapeutic
regimens, successful treatment of advanced forms of cancer is still a challenge and may …